Outlook Therapeutics says FDA approves LYTENAVA for wet AMD

• Outlook Therapeutics won FDA clearance for LYTENAVA (bevacizumab-vikg) to treat wet age-related macular degeneration.
• The decision makes LYTENAVA the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the US.
• The company expects about 12 years of US market exclusivity under the BPCIA.
• Launch preparations are underway, with US availability targeted before year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.